Compare CVGI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | TLSA |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 155.3M |
| IPO Year | 2004 | 2017 |
| Metric | CVGI | TLSA |
|---|---|---|
| Price | $4.51 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 657.7K | 179.7K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $110.00 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $1.29 | $1.04 |
| 52 Week High | $5.88 | $2.60 |
| Indicator | CVGI | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 56.52 |
| Support Level | $3.73 | $1.26 |
| Resistance Level | $4.45 | $1.44 |
| Average True Range (ATR) | 0.40 | 0.09 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 8.15 | 96.43 |
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.